Drug class gets stronger warning of heart risk
Drug class gets stronger warning of heart risk
The FDA will now require manufacturers of all thiazolidinediones (TZDs) to add a stronger "boxed" warning to the label highlighting the risk of heart failure. The change was implemented following an agency review of postmarketing adverse event reports that found cases of significant weight gain and edema, warning signs of heart failure. Healthcare professionals are encouraged to observe patients for excessive rapid weight gain, edema, and shortness of breath after beginning therapy with a TZD. If these signs appear, treatment with a TZD should be reconsidered and alternative treatment options discussed. The new update also added that TZDs should not be used in patients with established NYHA Class III or IV heart failure and is not recommended in patients with symptomatic heart failure. The affected drugs include rosiglitazone (Avandia, GlaxoSmithKline), pioglitazone (Actos, Takeda), rosiglitazone/glimepiride (Avandaryl, GSK), rosiglitazone/metformin (Avandamet, GSK), and pioglitazone/glimepiride (Duetact, Takeda).
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Challenges for Pharmacies in 2025: What to Expect and How to Prepare
January 8th 2025Pharmacy professionals are used to overcoming obstacles in this competitive, dynamic field. But the coming year will bring challenges affecting patient care, the industry workforce and their business. Pharmacies must be ready to do more than weather the storm; they need deliberate strategy and sophisticated tools to thrive amidst these obstacles. This white paper will discuss the issues and solutions that should be at the top of every pharmacy professional’s mind as they start the new year.
